| 2024-03-26 18:23 | CC:APS | Aptose Biosciences Inc (3) | 2.13 | SEDAR Annual Report803 | SEDAR Annual Report |
| 2024-03-26 18:16 | CC:APS | Aptose Biosciences Inc (3) | 2.13 | SEDAR MD & A815 | SEDAR MD & A |
| 2024-03-26 18:03 | CC:APS | Aptose Biosciences Inc (3) | 2.13 | SEDAR Audited Annual Financial Statements804 | SEDAR Audited Annual Financial Statements |
| 2024-03-26 16:26 | CC:APS | Aptose Biosciences Inc (3) | 2.13 | News Release200 | Aptose Biosciences spends $33.27M on R&D in 2023 |
| 2024-03-18 16:43 | CC:APS | Aptose Biosciences Inc (3) | 2.00 | News Release200 | Aptose to release 2023 results, host call March 26 |
| 2024-01-31 16:10 | CC:APS | Aptose Biosciences Inc (3) | 2.63 | News Release200 | Aptose closes financings for $13.7-million (U.S.) |
| 2024-01-26 10:25 | CC:APS | Aptose Biosciences Inc (3) | 2.64 | News Release200 | Aptose prices offering at $1.71 (U.S.) per share |
| 2023-12-11 01:17 | CC:APS | Aptose Biosciences Inc (3) | 3.80 | News Release200 | Aptose releases tuspetinib data from phase 1/2 study |
| 2023-11-30 17:13 | CC:APS | Aptose Biosciences Inc (3) | 3.32 | News Release200 | Aptose Biosciences adds executive duties to Payne |
| 2023-11-09 18:39 | CC:APS | Aptose Biosciences Inc (3) | 4.27 | SEDAR Interim MD & A813 | SEDAR Interim MD & A |
| 2023-11-09 18:30 | CC:APS | Aptose Biosciences Inc (3) | 4.27 | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
| 2023-11-09 16:09 | CC:APS | Aptose Biosciences Inc (3) | 4.27 | News Release200 | Aptose spends $8.25-million on R&D in Q3 |
| 2023-10-30 11:47 | CC:APS | Aptose Biosciences Inc (3) | 3.80 | News Release200 | Aptose talks Aptivate study results, ESH conference |
| 2023-10-26 11:51 | CC:APS | Aptose Biosciences Inc (3) | 3.49 | News Release200 | Aptose to release Q3 2023 results Nov. 9 |
| 2023-10-23 12:50 | CC:APS | Aptose Biosciences Inc (3) | 3.20 | News Release200 | Aptose to provide clinical update at ESH conference |
| 2023-09-06 14:09 | CC:APS | Aptose Biosciences Inc (3) | 5.59 | News Release200 | Aptose Biosciences closes $3M investment by Hanmi |
| 2023-08-10 16:49 | CC:APS | Aptose Biosciences Inc (3) | 5.15 | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
| 2023-08-10 16:33 | CC:APS | Aptose Biosciences Inc (3) | 5.15 | News Release200 | Aptose cash at $23.3-million at June 30 |
| 2023-07-27 16:17 | CC:APS | Aptose Biosciences Inc (3) | 5.20 | News Release200 | Aptose to release Q2 results, host call Aug. 10 |
| 2023-06-26 17:19 | CC:APS | Aptose Biosciences Inc (3) | 7.00 | News Release200 | Aptose regains Nasdaq compliance after share rollback |
| 2023-06-12 02:50 | CC:APS | Aptose Biosciences Inc (3) | 7.48 | News Release200 | Aptose trial complete; tuspetinib shows safety profile |
| 2023-06-05 12:11 | CC:APS | Aptose Biosciences Inc (2) | 0.58 | News Release200 | Aptose to complete 1:15 share rollback June 6 |
| 2023-06-02 18:45 | CC:APS | Aptose Biosciences Inc (2) | 0.58 | Rollback291 | Aptose Biosciences 1:15 rollback |
| 2023-05-31 12:22 | CC:APS | Aptose Biosciences Inc (2) | 0.56 | News Release200 | Aptose to provide tuspetinib, luxeptinib update June 10 |
| 2023-05-25 17:00 | CC:APS | Aptose Biosciences Inc (2) | 0.57 | News Release200 | Aptose enters $25M committed equity facility |
| 2023-05-23 18:30 | CC:APS | Aptose Biosciences Inc (2) | 0.64 | News Release200 | Aptose shareholders approve 1:15 share rollback |
| 2023-05-08 18:24 | CC:APS | Aptose Biosciences Inc (2) | 0.69 | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
| 2023-05-08 18:24 | CC:APS | Aptose Biosciences Inc (2) | 0.69 | SEDAR MD & A815 | SEDAR MD & A |
| 2023-05-08 16:19 | CC:APS | Aptose Biosciences Inc (2) | 0.69 | News Release200 | Aptose Biosciences spends $8.81M on R&D in Q1 2023 |